Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Reboxetine Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Axsome drug succeeds in narcolepsy symptoms trial
    Axsome drug succeeds in narcolepsy symptoms trial

    26 Mar 2024

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/axsome-narcolepsy-drug-clinical-trial-results/711249/

    Jacob Bell BIOPHARMADIVE
    26 Mar 2024
    Share Share
    Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc.
    Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc.

    13 Jan 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/01/13/1969353/0/en/Axsome-Therapeutics-Enters-into-Exclusive-License-Agreement-with-Pfizer-Inc-for-Pfizer-s-Reboxetine-Clinical-and-Nonclinical-Data-and-for-New-Phase-3-Esreboxetine-Product-Candidate.html

    GLOBENEWSWIRE
    13 Jan 2020
    Share Share
    Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial
    Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial

    21 Oct 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/axsome-therapeutics-completes-patient-enrollment-in-the-concert-phase-2-trial-of-axs-12-in-narcolepsy/?s=95

    BIOSPACE
    21 Oct 2019
    Share Share
    Axsome completes patient enrollment in CONCERT ph2 trial of AXS-12 in narcolepsy
    Axsome completes patient enrollment in CONCERT ph2 trial of AXS-12 in narcolepsy

    21 Oct 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=118902&sid=2

    PHARMABIZ
    21 Oct 2019
    Share Share